Results 51 to 60 of about 92,407 (261)

Trends in analgesia prescribing in primary care in Ireland and England between 2014 and 2022: A repeated cross‐sectional study

British Journal of Clinical Pharmacology, EarlyView.
Aims Analgesic medicines are an important component of pain management, with different medicines carrying different risks and benefits. The aim of this study was to examine trends in analgesic prescribing in Ireland and England between 2014 and 2022. Methods Monthly data on medicines prescribed and dispensed in primary care were used. For Ireland, data
Molly Mattsson, Michelle Flood, Brian MacKenna, Emma Wallace, Fiona Boland, Ciara Kirke, Mary E. Walsh, Tom Fahey, Frank Moriarty   +8 more
wiley   +1 more source

Deprescribing drugs with anticholinergic effects in older patients with increased risk of dementia in the multicomponent intervention study AgeWell.de

British Journal of Clinical Pharmacology, EarlyView.
Aim Drugs with anticholinergic effects are often considered as potentially inappropriate medications, especially for older patients, and deprescribing such drugs may improve cognitive function. The aim was to investigate the effectiveness of counselling on drug risks as part of a multimodal intervention to prevent cognitive decline. Methods The AgeWell.
Laura K. Lepenies, Hanna M. Seidling, Alexander Pabst, Melanie Luppa, Juliane Döhring, Martin Williamson, Thomas Frese, Jochen Gensichen, Wolfgang Hoffmann, Hanna Kaduszkiewicz, Hans‐Helmut König, Jochen René Thyrian, Birgitt Wiese, Steffi G. Riedel‐Heller, David Czock   +14 more
wiley   +1 more source

Constipation in CKD

Kidney International Reports, 2020
Constipation is one of the most common gastrointestinal disorders among patients with chronic kidney disease (CKD) partly because of their sedentary lifestyle, low fiber and fluid intake, concomitant medications (e.g., phosphate binders), and multiple ...
Keiichi Sumida, Kunihiro Yamagata, Csaba P. Kovesdy   +2 more
doaj   +1 more source

The Aging Gut–Brain Axis: Effects of Dietary Polyphenols and Metal Exposure

Chronic Diseases and Translational Medicine, EarlyView.
The influence of gut microbiota on brain health ABSTRACT Diet provides essential metals, which are required for the growth, development, and well‐functioning of the body. Nonetheless, some natural and human activities add toxic heavy metals to the diet, consequently introducing them to our bodies, resulting in several disorders and death. The intestine,
Luqi Cao, Saurabh Kumar Jha, Neha Gupta, Xiang Chen, Renuka Soni, Luoxi Yuan, Rashi Srivastava, Zhe‐Sheng Chen   +7 more
wiley   +1 more source

Economic burden associated with chronic constipation in Sweden: a retrospective cohort study

ClinicoEconomics and Outcomes Research, 2014
Sara Bruce Wirta,1 Paul Hodgkins,2 Alain Joseph3 1IMS Health, Stockholm, Sweden; 2Shire, Wayne, PA, USA; 3Shire, Eysins, Switzerland Background: Chronic constipation is a common condition, but few studies have assessed its cost and impact on resource ...
Bruce Wirta S, Hodgkins P, Joseph A
doaj  

Relative Bioavailability, Food Effect, and Bioequivalence Studies to Assess a New Zanubrutinib 160‐mg Tablet: Results From 2 Phase 1 Studies in Healthy Volunteers

Clinical Pharmacology in Drug Development, EarlyView.
Abstract Zanubrutinib is a next‐generation Bruton tyrosine kinase inhibitor approved for treating B‐cell malignancies. Two phase 1 studies evaluated a new 160‐mg zanubrutinib tablet versus 80‐mg capsules. In study BGB‐3111‐115 (n = 43), a randomized 3‐period crossover trial, relative bioavailability and food effects were assessed.
Bilal Tariq, Chester Lin, Vaibhav Mundra, Yang Gao, Dan Zhang, Ying C. Ou   +5 more
wiley   +1 more source

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Ascending Doses and Dose Titration of Bexicaserin in Healthy Participants in a Randomized, Double‐Blind, Placebo‐Controlled Study

Clinical Pharmacology in Drug Development, EarlyView.
Abstract Bexicaserin (LP352) is a selective superagonist of the 5‐hydroxytryptamine 2C (5‐HT2C) receptor currently in development for the treatment of seizures that arise from developmental and epileptic encephalopathies. This phase 1, double‐blind, placebo‐controlled multiple ascending dose (MAD) study assessed the safety, tolerability, and ...
Jonathan Williams, Rosa Chan, Chad Orevillo, Gale O'Connell, Dewey McLin, Shikha Polega, Nuggehally R. Srinivas, Randall Kaye   +7 more
wiley   +1 more source

Assessment of Pharmacokinetic Drug Interaction of Asciminib with Atorvastatin in Healthy Participants

Clinical Pharmacology in Drug Development, EarlyView.
Abstract Asciminib is the first BCR::ABL1 inhibitor that Specifically Targets the ABL Myristoyl Pocket (STAMP) in patients with chronic myeloid leukemia. This phase 1, two‐treatment‐period, drug‐drug interaction study evaluated the effect of steady‐state asciminib on the pharmacokinetics of atorvastatin.
Matthias Hoch, Wendy Weis, Felix Huth, Seshulatha Jamalapuram, Michelle Quinlan, Amarnath Bandaru, Suleyman Eralp Bellibas, Asmae Mirkou, Shruti Kapoor, Shefali Kakar   +9 more
wiley   +1 more source

Safety, Pharmacokinetics, and Pharmacodynamics of Osivelotor for Sickle Cell Disease: First‐in‐Human Studies in Healthy Participants and Patients

Clinical Pharmacology &Therapeutics, EarlyView.
The investigational agent osivelotor, a small molecule hemoglobin (Hb) modifier in development for the treatment of sickle cell disease (SCD), acts by increasing Hb‐oxygen affinity and inhibiting the polymerization of sickle Hb. We report safety, pharmacokinetic (PK), and pharmacodynamic (PD) data from the first two phase 1 clinical trials of ...
Eleanor A. Lisbon, R. Clark Brown, Andrew Redfern, Ken Duchin, Aline Barth, Erika S. Roberts, Polo Gaputan, Kobina Dufu, Arthur Lo, Mira Patel Pochron, David R. Archer, Wai Chin, Karena Kong, Carla B. Washington, Adeyemi Adenola, Eric I. Zimmerman   +15 more
wiley   +1 more source

Drug‐Induced QT Prolongation: Associations Between Risk Classifications in a Swedish Clinical Decision Support System and Clinical Outcomes

Clinical Pharmacology &Therapeutics, EarlyView.
Potential adverse drug events can be signaled in Clinical Decision Support Systems (CDSSs). This study validated a Swedish CDSS (Janusmed Risk Profile) by investigating associations between calculated risk classifications of drugs with QT‐prolonging potential and registered related clinical outcomes.
Ola Nordqvist, Olof Björneld, Patrick Bergman, Björn Wettermark, Alisa Lincke, Marine L. Andersson, Tora Hammar   +6 more
wiley   +1 more source